Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;23(3):83-92.
doi: 10.1297/cpe.23.83. Epub 2014 Aug 6.

Effect of growth hormone treatment on quality of life in Japanese children with growth hormone deficiency: an analysis from a prospective observational study

Toshiaki Tanaka  1 , Tomonobu Hasegawa  2 , Keiichi Ozono  3 , Hiroyuki Tanaka  4 , Susumu Kanzaki  5 , Susumu Yokoya  6 , Kazuo Chihara  7 , Noriyuki Iwamoto  8 , Yoshiki Seino  9
Affiliations

Effect of growth hormone treatment on quality of life in Japanese children with growth hormone deficiency: an analysis from a prospective observational study

Toshiaki Tanaka et al. Clin Pediatr Endocrinol. 2014 Jul.

Abstract

The aim of this study was to assess changes in quality of life (QoL) in Japanese children with GH deficiency (GHD) after 12 mo of GH treatment or with idiopathic short stature (ISS) after 12 mo without treatment. Children with GHD were treated with GH after enrollment. Outcome measures included the parent-rated Child Behavior Checklist (CBCL), the Youth Self-Report Form (YSR), and height standard deviation scores (SDS). Total CBCL scores significantly decreased in children with GHD (n = 152, mean change (standard deviation [SD]) = -3.42 [11.21]) and ISS (n = 129, mean change = -4.82 [10.09]) after 12 mo (p < 0.001). Total YSR scores (mean change = -9.21 [14.07]) and height SDS (mean change = 0.35 [0.38]) significantly decreased in children with GHD (p < 0.001), but were unchanged in children with ISS. The change in total YSR score was significantly correlated with the change in height SDS in children with GHD (r = -0.516, p = 0.003). Our findings demonstrate that GH treatment can improve QoL in Japanese children with GHD. The correlation between the changes in total YSR score and height SDS demonstrated that increased height resulted in improved QoL.

Keywords: Child Behavior Checklist; GH deficiency; GH treatment; Youth Self-Report; idiopathic short stature.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Change from study entry in parent-rated Child Behavior Checklist (CBCL) scores in children with GH deficiency (GHD, n = 66) or idiopathic short stature (ISS, n = 61) after 12 mo. Children with GHD received GH treatment for the entire 12 mo, whereas children with ISS were not treated. Data are shown as mean ± standard deviation. * Indicates a statistically significant change from study entry (p < 0.05).
Fig. 2.
Fig. 2.
Change from study entry in Youth Self-Report (YSR) scores in children with GH deficiency (GHD, n = 28) or idiopathic short stature (ISS, n = 13) after 12 mo. Children with GHD received GH treatment for the entire 12 mo, whereas children with ISS were not treated. Data are shown as mean ± standard deviation. * Indicates a statistically significant change from study entry (p < 0.05).
Fig. 3.
Fig. 3.
Scatter plots showing the correlations between the changes in total (A) and attention problems (B) Youth-Self Report (YSR) scores and the change in height standard deviation scores (SDS) after 12 mo of GH treatment in children with GH deficiency (n = 27).
See this image and copyright information in PMC

References

    1. Lifshitz F, Cervantes CD. Short stature. In: Lifshitz F, editor. Pediatric endocrinology. New York: Marcel Dekker; 1996. p. 1–18.
    1. Krysiak R, Gdula-Dymek A, Bednarska-Czerwińska A, Okopień B. Growth hormone therapy in children and adults. Pharmacol Rep 2007;59: 500–16 - PubMed
    1. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010;14: 1–209, iii–iv iii–iv. - PubMed
    1. Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007; CD004440 - PubMed
    1. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84: 4307–16. doi: 10.1210/jcem.84.12.6189 - DOI - PubMed

LinkOut - more resources